Bacterial and immune-cell diversity shape phagosome acidification in tuberculosis

Tuberculosis remains a complex disease because outcomes depend on more than just the bacterium itself. Host immune differences and genetic variation among Mycobacterium tuberculosis (MTB) strains both shape whether an infection is contained or progresses, but how these two sources of diversity interact has been poorly understood. Paolo Miotto and collaborators set out to explore that interaction directly by studying the interface between human macrophages and MTB strains. Instead of treating either the host or the pathogen as uniform, the team deliberately considered macrophage phenotypic variability — the idea that macrophages can exist in different activation states such as M1 and M2 — alongside genetic differences among MTB lineages. Using single-cell techniques to examine these encounters at high resolution, the researchers asked whether different bacterial lineages provoke the same or different responses in distinct macrophage types. The work focused on a key cellular process: phagosome acidification, the drop in pH inside the vesicle that engulfs bacteria and is critical for killing many pathogens. By bringing together both sides of the host-pathogen relationship, the study aimed to reveal the range of possible outcomes when diverse macrophages meet diverse MTB lineages.

To capture the fine-grained interactions between cells and bacteria, the investigators relied on single-cell techniques that can reveal variation that would be hidden in bulk measurements. They exposed human macrophages with defined phenotypes (M1 and M2) to a variety of Mycobacterium tuberculosis lineages and then measured how the phagosomes containing bacteria acidified. The central result is that MTB lineages do not behave identically across macrophage types: different lineages fine-tune phagosome acidification in distinct ways depending on whether the host cell is an M1 or an M2 macrophage. In practical terms, this means that a given bacterial strain might trigger stronger acidification in one macrophage phenotype but weaker acidification in another, and those differences occur at the single-cell level, producing very heterogeneous host-pathogen interactions even within the same culture. The data therefore reveal a combinatorial pattern in which both macrophage phenotype and bacterial genotype together determine the acidification outcome, rather than either factor alone.

These findings carry important implications for how we think about host-directed strategies to treat tuberculosis. The study highlights that therapies designed to boost phagolysosomal maturation, for example, may not work uniformly against all MTB lineages or in all patients because macrophage populations are themselves diverse. The authors note that the multiplicity of outcomes emerging from the interplay between macrophage phenotypes and MTB lineages could help explain why some interventions succeed in some contexts but fail in others. Rather than assuming a single immune manipulation will help all patients, the results argue for tailoring approaches that account for both bacterial diversity and host cell heterogeneity. In short, appreciating this two-sided variability should inform the design and testing of next-generation host-directed therapies and could help researchers predict which combinations of bacterial lineage and macrophage phenotype are most likely to respond to interventions targeting phagolysosomal maturation.